tiprankstipranks
Trending News
More News >
Healius Limited (AU:HLS)
:HLS
Advertisement

Healius Limited (HLS) AI Stock Analysis

Compare
46 Followers

Top Page

AU:HLS

Healius Limited

(Frankfurt:HLS)

Rating:46Neutral
Price Target:
AU$0.50
▼(-37.50%Downside)
Healius Limited's overall stock score is primarily impacted by its weak financial performance, characterized by consistent net losses and increased leverage. While technical indicators suggest the stock is oversold, the valuation remains unattractive due to negative earnings and absent dividend yield. The lack of new earnings call insights or corporate events leaves the current analysis unchanged.

Healius Limited (HLS) vs. iShares MSCI Australia ETF (EWA)

Healius Limited Business Overview & Revenue Model

Company DescriptionHealius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
How the Company Makes MoneyHealius Limited generates revenue through multiple streams within the healthcare sector. The primary source of income is derived from its pathology services, which include laboratory testing and diagnostic services. This segment serves a wide range of healthcare needs, from routine blood tests to more complex genetic testing, catering to hospitals, clinics, and individual patients. Another significant revenue stream is from diagnostic imaging services, providing advanced imaging techniques such as MRI, CT scans, and ultrasounds. Additionally, Healius operates day hospitals, which offer outpatient surgical procedures, further contributing to its revenue. The company benefits from partnerships with healthcare providers and government health programs, which support its financial stability and growth. By leveraging its extensive network and expertise in healthcare services, Healius maintains a strong market presence and continues to expand its offerings.

Healius Limited Financial Statement Overview

Summary
Healius Limited faces significant profitability challenges with negative net profit margins and increased leverage. The company shows some strength in generating operating cash flows despite net losses, but declining free cash flow growth raises concerns about future financial flexibility.
Income Statement
45
Neutral
Healius Limited has faced declining revenue, with a Revenue Growth Rate of 2.31% from 2023 to 2024, indicating stagnation compared to previous years. The Gross Profit Margin stands at 31.00% for 2024, showing some efficiency in generating profit from sales, but the Net Profit Margin is significantly negative at -36.98% due to substantial net losses, which is a red flag for profitability. The EBIT Margin of 3.75% reflects limited operating efficiency, while a negative EBITDA Margin suggests challenges in covering operating expenses without considering depreciation and amortization.
Balance Sheet
50
Neutral
The Balance Sheet indicates a moderate level of financial stability. The Debt-to-Equity Ratio has increased to 1.53 in 2024, suggesting higher leverage and potential risk if earnings do not improve. However, the company maintains an Equity Ratio of 34.89%, indicating that a substantial portion of assets is financed by equity. Return on Equity is currently negative at -62.05%, highlighting the company's struggle to generate returns for shareholders amid net losses.
Cash Flow
60
Neutral
Healius Limited demonstrates some strength in cash flow generation, with Operating Cash Flow to Net Income Ratio at -0.37, reflecting better cash flow management than net income suggests. The Free Cash Flow to Net Income Ratio is -0.27, indicating that despite net losses, the company is generating positive free cash flow. However, Free Cash Flow Growth Rate is negative at -24.54%, showing a decline in cash available for expansion and debt reduction.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.75B1.71B2.29B1.90B1.58B
Gross Profit1.52B341.70M779.20M526.50M511.70M
EBITDA-298.10M-57.80M734.80M470.40M300.80M
Net Income-645.80M-367.80M307.90M43.70M-70.50M
Balance Sheet
Total Assets2.98B3.65B4.14B3.78B4.59B
Cash, Cash Equivalents and Short-Term Investments60.10M115.30M81.30M70.10M137.50M
Total Debt1.60B1.77B1.78B1.44B1.75B
Total Liabilities1.94B2.15B2.22B1.92B2.66B
Stockholders Equity1.04B1.51B1.92B1.86B1.93B
Cash Flow
Free Cash Flow173.80M230.30M480.30M432.00M307.80M
Operating Cash Flow237.80M306.40M573.80M493.30M380.20M
Investing Cash Flow-63.00M67.30M-401.70M386.90M-121.90M
Financing Cash Flow-259.00M-339.70M-163.50M-952.10M-233.60M

Healius Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.80
Price Trends
50DMA
0.84
Negative
100DMA
0.93
Negative
200DMA
1.00
Negative
Market Momentum
MACD
-0.01
Negative
RSI
54.94
Neutral
STOCH
68.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HLS, the sentiment is Neutral. The current price of 0.8 is above the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.84, and below the 200-day MA of 1.00, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.94 is Neutral, neither overbought nor oversold. The STOCH value of 68.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:HLS.

Healius Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
AU$13.82B24.556.86%3.78%10.15%6.20%
69
Neutral
AU$553.82M18.3218.39%4.43%7.80%99.87%
55
Neutral
AU$300.02M-0.87%6.62%14.24%-109.59%
53
Neutral
AU$998.11M110.291.14%2.16%7.83%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
46
Neutral
AU$580.91M-4.46%-7.82%98.08%
45
Neutral
AU$81.77M-47.52%44.61%16.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HLS
Healius Limited
0.82
-0.26
-24.19%
AU:GSS
Genetic Signatures Ltd.
0.34
-0.42
-55.26%
AU:SHL
Sonic Healthcare Limited
28.32
2.66
10.37%
AU:IDX
Integral Diagnostics Ltd.
2.72
0.30
12.40%
AU:ACL
Australian Clinical Labs Ltd
2.87
0.34
13.44%
AU:MVF
Monash IVF Group Ltd
0.80
-0.49
-37.98%

Healius Limited Corporate Events

Mitsubishi UFJ Financial Group Increases Stake in Healius Limited
Jul 1, 2025

Healius Limited has announced a change in the substantial holding of Mitsubishi UFJ Financial Group, Inc. in its shares. The voting power of Mitsubishi UFJ Financial Group, Inc. has increased from 5.22% to 6.42%, indicating a significant shift in shareholder dynamics. This change reflects Mitsubishi UFJ Financial Group, Inc.’s growing influence within the company, which could have implications for Healius Limited’s strategic decisions and stakeholder interests.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Change in Substantial Holder Interests
Jun 30, 2025

Healius Limited has announced a change in the interests of a substantial holder, First Sentier Investors Holdings Pty Limited, which is indirectly owned by Mitsubishi UFJ Financial Group. This change involves a shift in voting power and relevant interests in the company’s securities. The update reflects the substantial holder’s increased control over voting rights and securities disposal, impacting the company’s shareholder structure and potentially influencing its strategic decisions.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Norges Bank Acquires Substantial Stake in Healius Limited
Jun 27, 2025

Healius Limited has announced a significant change in its shareholder structure with Norges Bank, the Central Bank of Norway, becoming a substantial holder. Norges Bank now holds a 5.21% voting power in Healius Limited, with its shares managed through Citicorp Nominees Pty Limited and J.P. Morgan Nominees Australia Ltd. This development marks a notable shift in the company’s ownership landscape, potentially impacting its strategic direction and stakeholder interests.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Mitsubishi UFJ Financial Group Acquires Substantial Stake in Healius Limited
Jun 25, 2025

Healius Limited has announced that Mitsubishi UFJ Financial Group, Inc. has become a substantial holder in the company, acquiring a 5.22% voting power through its relevant interests in First Sentier Investors Holdings Pty Limited and Morgan Stanley. This development signifies a significant investment by Mitsubishi UFJ Financial Group, potentially impacting Healius Limited’s market dynamics and shareholder composition, as well as indicating confidence in the company’s future prospects.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

MUFG Acquires Substantial Holding in Healius Limited
Jun 24, 2025

Mitsubishi UFJ Financial Group (MUFG) has announced a substantial holding in Healius Limited, with First Sentier Investors Holdings Pty Limited and its subsidiaries having significant voting power in the company. This development indicates a strategic interest by MUFG in Healius, potentially impacting the company’s governance and strategic direction, as well as influencing its market positioning.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

State Street Corporation Ceases Substantial Holding in Healius Limited
Jun 24, 2025

Healius Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders in the company as of June 20, 2025. This change in substantial holding could impact the company’s shareholder structure and influence in the market, potentially affecting its strategic decisions and stakeholder interests.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Reports Change in Substantial Holder Interests
Jun 16, 2025

Healius Limited has experienced a change in the interests of a substantial holder, as reported on June 16, 2025. The notice indicates that State Street Bank and Trust Company, along with its subsidiaries, has adjusted its relevant interest in voting securities of Healius Limited. This shift in voting power could potentially impact the company’s governance and decision-making processes, reflecting the dynamic nature of shareholder interests in the company.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Sees Increased Stake by Australian Retirement Trust
Jun 12, 2025

Healius Limited has announced a change in the substantial holding of its shares by Australian Retirement Trust Pty Ltd, which now holds an 8.865% voting power, up from 7.814%. This increase in voting power signifies a strengthened position for the Australian Retirement Trust within Healius Limited, potentially impacting the company’s governance and strategic decisions.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Perpetual Limited Ceases to be Substantial Holder in Healius Limited
May 29, 2025

Healius Limited announced that Perpetual Limited and its related bodies corporate have ceased to be substantial holders in the company as of May 27, 2025. This change in shareholding could impact Healius’s market dynamics and stakeholder relationships, as substantial holders often influence company decisions and strategic directions.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Strengthens Leadership with New Company Secretary Appointment
May 29, 2025

Healius Limited has announced the appointment of Kylie Brown as a Company Secretary, effective 29 May 2025. This strategic appointment, alongside the continued service of Stephen Humphries and Gillian Nairn in their respective roles, reinforces Healius’s commitment to maintaining robust communication and compliance with ASX Listing Rules, potentially enhancing its operational efficiency and stakeholder confidence.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Healius Limited Announces Substantial Holder Interest Change
May 21, 2025

Healius Limited has announced a change in the interests of a substantial holder, with State Street Corporation and its subsidiaries adjusting their voting power in the company. This update reflects the dynamic nature of shareholder interests and could influence the company’s governance and decision-making processes.

The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.

Spheria Reduces Stake in Healius Limited
May 9, 2025

Healius Limited has experienced a change in the interests of its substantial holder, Spheria Asset Management Pty Ltd, which has decreased its voting power from 8.59% to 7.34%. This change reflects a reduction in the number of shares held by Spheria, impacting the company’s shareholder dynamics and potentially influencing future decision-making processes within Healius.

Healius Limited Announces New Dividend Distribution
May 5, 2025

Healius Limited has announced a new dividend distribution for its shareholders, with a distribution amount of AUD 0.413 per share. The ex-date for the dividend is set for May 9, 2025, with a record date of May 12, 2025, and payment scheduled for May 23, 2025. This announcement reflects Healius Limited’s ongoing commitment to delivering value to its shareholders and may positively impact its market positioning by reinforcing investor confidence.

Healius Limited Declares Special Dividend and Secures New Debt Facility
May 5, 2025

Healius Limited has announced a fully franked special dividend of 41.3 cents per share, amounting to approximately $300 million, with key dates set for May 2025. Additionally, the company has secured a new $300 million syndicated bank facility to replace its existing $680 million facility, aiming to be in a net cash position by the end of the fiscal year, reflecting a strategic move to optimize financial operations and maintain industry competitiveness.

Healius Completes Sale of Lumus Imaging, Refocuses on Pathology
May 1, 2025

Healius Limited has completed the sale of Lumus Imaging to Affinity Equity Partners for $822 million, allowing Healius to focus on its pathology strategy and streamline operations. The transaction will enable Healius to pay a special dividend and provide transitional services to Lumus Imaging for up to eighteen months, ensuring a smooth transition for both the company and its patients.

Healius Limited Updates CEO Employment Terms and Incentive Structure
Apr 27, 2025

Healius Limited has announced changes to the employment terms of its CEO, Paul Anderson, transitioning his role to permanent ongoing employment and increasing his fixed annual remuneration. The CEO’s incentive arrangements for FY27 will align with other key management personnel, including short-term and long-term incentives, reflecting a strategic move to enhance leadership stability and align executive compensation with company performance goals.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025